
    
      This is a Phase III single-blind, randomized, controlled, non-inferiority multi-center trial
      in American Society of Anesthesiologists (ASA) Class III/IV patients undergoing elective
      surgery, comparing remimazolam to propofol for induction and maintenance of intravenous
      anesthesia. In accordance with general anesthetic standard regimen, remimazolam or propofol,
      will be administered together with remifentanil as analgesic agent, and with a neuromuscular
      blocker to facilitate intubation and achieve muscle relaxation
    
  